Abstract
OBJECTIVE: Flebogrif introduces a novel mechanochemical ablation technique for the treatment of incompetent saphenous veins. However, studies evaluating its efficacy as a relatively new treatment technique remain scarce. This study aimed to evaluate 1-year clinical outcomes after its application. METHODS: We conducted a retrospective analysis of 61 patients with 105 incompetent great saphenous veins who underwent treatment with Flebogrif. Primary outcomes included anatomical success rates at 1, 6, and 12 months post procedure, with secondary outcomes including adverse events, pain scores, Revised Venous Clinical Severity score, Chronic Venous Insufficiency Quality of Life Questionnaire scores, time to resumption of normal activities, and foam sclerosant dosage. RESULTS: The anatomical success rates were 100% at 1 month, 98.4% at 6 months, and 95.4% at 12 months. Adverse events were mild, with no severe complications such as paresthesia or deep vein thrombosis. Flebogrif facilitated the treatment of multiple veins without related adverse events, averaging a foam sclerosant dosage of 17.70 ± 6.13 mL per procedure. Both the Revised Venous Clinical Severity score and Chronic Venous Insufficiency Quality of Life Questionnaire scores demonstrated a significant reduction from baseline. CONCLUSIONS: Flebogrif is a safe and effective technique for the treatment of multiple incompetent saphenous veins.